Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H3B-6545 in ER+/HER2- Advanced Breast Cancer
NCT03250676Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2017
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of H3B-6545 in breast cancer, sponsored by Eisai Co., Ltd.. Started Aug 2017; status: completed.
02
Drugs
H3B-6545
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03250676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03250676.